核心观点AK112 已经在NSCLC 开展3 项全球3 期临床,本次summit 与辉瑞合作将更注重在肺癌领域之外的适应症探索。与辉瑞一系列ADCs 药物的联合方案开发,将有助于更快速、更深入和充分地挖掘依沃西作为新一代肿瘤免疫治疗双抗新药在包括中国在内的全球市场的临床价值和商业价值,建立依沃西在肿瘤治疗领域持续的迭代优势。后续可以关注:(1)AK104 持续放量,宫颈癌1L获批;(2)AK112...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.